IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1167/iovs.09-3445 on April 15, 2009
(Investigative Ophthalmology and Visual Science. 2009;50:4429-4435.)
© 2009 by The Association for Research in Vision and Ophthalmology, Inc.
doi:10.1167/iovs.09-3445

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
iovs.09-3445v1
50/9/4429    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Lewis, G. P.
Right arrow Articles by Fisher, S. K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewis, G. P.
Right arrow Articles by Fisher, S. K.

Müller Cell Reactivity and Photoreceptor Cell Death Are Reduced after Experimental Retinal Detachment Using an Inhibitor of the Akt/mTOR Pathway

Geoffrey P. Lewis,1 Ethan A. Chapin,1 Jiyun Byun,2 Gabriel Luna,1 David Sherris,3 and Steven K. Fisher1,4,5

1From the Neuroscience Research Institute, 4Center for Bio-Image Informatics, and 5Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, California; 2Mayachitra, Inc., Santa Barbara, California; and 3Paloma Pharmaceuticals, Inc., Jamaica Plain, Massachusetts.

PURPOSE. To test the effect of Palomid 529, an inhibitor of the Akt/mTOR pathway, on Müller cell proliferation, subretinal glial scar formation, and photoreceptor survival after experimental retinal detachment (RD).

METHODS. Palomid 529 (600 µg) in balanced salt solution or balanced salt solution alone was injected intravitreally immediately after RD into the right eyes of 12 rabbits. Ten micrograms of BrdU was injected intravitreally on day 3. Animals were killed on day 3 or 7, at which time retinal sections were labeled with anti-BrdU to detect dividing cells, with anti-vimentin to identify Müller cells, and with the isolectin B4 to identify microglia and macrophages. Outer nuclear layer (ONL) thickness was measured from fluorescence-labeled nuclear-stained sections. Labeling was imaged using confocal microscopy. Six additional animals received either drug or balanced salt solution injections into normal eyes, and paraffin sections were stained with hematoxylin and eosin.

RESULTS. In the drug-treated eyes there was a significant decrease in the number of anti-BrdU–labeled Müller cells, the number and size of subretinal scars, and the number of isolectin B4-labeled cells. The ONL was also significantly thicker, and there was no evidence of toxic effects.

CONCLUSIONS. Palomid 529 is an effective suppressor of Müller cell proliferation, glial scar formation, and photoreceptor cell death in a rabbit model of RD. This suggests that inhibiting the Akt/mTOR signal transduction pathway may be an effective strategy to decrease proliferation and photoreceptor cell death induced by detachment and perhaps represents a novel therapy for related human diseases such as proliferative vitreoretinopathy.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the Association for Research in Vision and Ophthalmology